You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

14 Results
Guidelines and Advice
Status: Current
ID: SCT-2
Version: 2
Nov 2019
Drug
Other Name(s): Vesanoid®
Jun 2019
Drug
Other Name(s): Thalomid®
Jun 2019
Drug
Other Name(s): Lanvis®
Jun 2019
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Jun 2019
Regimen
Cancer Type:
Sarcoma, 
Desmoid Tumour
Intent: Curative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Curative
Jun 2019
Regimen
Intent: Palliative
May 2019
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    tamoxifen
May 2019
Regimen
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
  • triptorelin
May 2019
Guidelines and Advice
Mar 2019

Pages